Inflammation and Alzheimer's disease: Relationships between pathogenic mechanisms and clinical expression

Experimental Neurology

Volumn 154, Issue 1, 1998, Pages 89-98

  Eikelenboom, P ^a   Rozemuller, J M ^a   Van Muiswinkel, F L ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Activated microglia; Acute phase response; Alzheimer's disease; Delirium; Down's syndrome

Indexed keywords

ACUTE PHASE RESPONSE; ALZHEIMER DISEASE; ARTICLE; BRAIN ISCHEMIA; DELIRIUM; DEMENTIA; DOWN SYNDROME; HEAD INJURY; HUMAN; INFLAMMATORY DISEASE; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0032213445     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1998.6920     Document Type: Article

References (121)

1. Abraham C. R., Selkoe D. J., Potter H. Immunohistochemical identification of the serine protease inhibitor α1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell. 52:1988;487-501.
2. Abraham C. R., Potter H. Alzheimer's disease: Recent advances in understanding the brain amyloid deposits. Biotechnology. 7:1989;147-153.
3. Afagh A., Cummings B. J., Cribbs D. H., Cotman C. W., Tenner A. J. Localization and cell association of C1q in Alzheimer's disease brain. Exp. Neurol. 138:1996;22-32.
4. Aisen P. S., Davis K. L. Inflammatory mechanisms in Alzheimer's disease: Implications for therapy. Am. J. Psychiat. 151:1994;1105-1113.
5. Akiyama H., McGeer P. L. Brain microglia constitutively express β2-integrins. J. Neuroimmunol. 30:1990;81-93.
6. Akiyama H., Kawamata T., Dedhar S., McGeer P. L. Immuno-histochemical localization of vitronectin, its receptor and beta-3 integrin in Alzheimer brain tissue. J. Neuroimmunol. 32:1991;19-28.
7. Altstiel L. D., Lawlor B., Mohs R., Schmeidler J., Dalton A., Mehta P., Davis K. Elevated alpha 1-antichymotrypsin serum levels in a subset of non-demented first-degree relatives of Alzheimer's disease patients. Dementia. 6:1995;17-20.
8. Bauer J., Strauss S., Schreiter-Gasser U., Ganter U., Schlegel, Witt I., Volk B., Berger M. Interleukin-6 and alpha2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett. 285:1991;111-114.
9. Blalock J. E. The syntax of immune-neuroendocrine communication. Immunol. Today. 15:1994;504-511.
10. Blom M. M. A. A., van Muiswinkel F. L., Eikelenboom P. Mechanims of inflammation in Alzheimer's disease. Ann. Psychiat. 6:1996;1-12.
11. Bornebroek M., Haan J., Maat-Schieman M. L. C., van Duinen S. G., Roos R. A. C. Heriditary cerebral hemorrhage with amyloidisis-Dutch type: I-A review of clinical, radiologic and genetic aspects. Brain Pathol. 6:1996;111-114.
12. Brachova L., Lue L. F., Schultz J., el Rashidy T., Rogers J. Association cortex, cerebellum, and serum concentrations of C1q and factor B in Alzheimer's disease. Mol. Brain Res. 18:1993;329-334.
13. Breitner J. C. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annu. Rev. Med. 47:1996;401-411.
14. Choi-Miura N. H., Khara Y., Fukuchi K., Takeda M., Nakano Y., Tobe T., Tomita M. SP40,40 is a constituent of Alzheimer's amyloid. Acta Neuropathol. 83:1992;260-264.
15. Cannella B., Raine C. S. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol. 37:1995;424-435.
16. Davies P., Maloney A. J. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. ii:1976;1403.
17. Dickson D. W., Lee S. C., Mattiace L. A., Yen S. C., Brosnan C. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia. 7:1993;75-83.
18. Dickson D. W. The pathogenesis of senile plaques. J. Neuropathol. Exp. Neurol. 56:1997;321-339.
19. Eikelenboom P., Stam F. C. Immunoglobulins and complement factors in senile plaques. Acta Neuropathol. 57:1982;239-242.
20. Eikelenboom P., Hack C. E., Rozemuller J. M., Stam F. C. Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch. B (Cell Pathol.). 56:1989;259-262.
21. Eikelenboom P., Rozemuller J. M., Fraser H., Berkenbosch F., Kamhorst W., Stam F. C. Neuroimmununlogical mechanisms in cerebral amyloid deposition in Alzheimer's disease. Frontiers in Alzheimer Research. 1991;Elsevier. p. 259-271.
22. Eikelenboom P., Rozemuller J. M., Kraal G., Stam F. C., McBride P. A., Bruce M. E., Fraser H. Cerebral amyloid deposits in Alzheimer's disease but not in scrapie-affected mice are closely associated with a local inflammatory response. Virchows Arch. B (Cell Pathol.). 60:1991;329-336.
23. Eikelenboom P., Hack C. E., Kamphorst W., van der Valk P., Van Nostrand W. E., Rozemuller J. M. The sequence of neuroimmunological events in cerebral amyloid plaque formation in Alzheimer's disease. Corain B., Iqbal K., Nicolini M., Winblad B., Wisniewski H. M., Zatta P. F. Alzheimer's Disease: Advances in Clinical and Basic Research. 1993;165-170 Wiley, Chichester.
24. Eikelenboom P., Zhan S. S., Kamphorst W., van der Valk P., Rozemuller J. M. Cellular and substrate adhesion molecules (integrins) and their ligands in cerebral amyloid plaques in Alzheimer's disease. Virchows Arch. 424:1994;421-427.
25. Eikelenboom P., Zhan S. S., van Gool W. A., Allsop D. Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol. Sci. 15:1994;147-150.
26. Eikelenboom P., Veerhuis R. The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Neurobiol. Aging. 17:1996;673-680.
27. Emsley J., White H. E., O'Hara B. P., Oliva G., Srinivasan N., Tickle I. J., Blundell T. L., Pepys M. B., Wood S. P. Structure of pentameric human serum amyloid P component. Nature. 367:1994;338-345.
28. Eriksson S., Janciauskiene S., Lannfelt L. α1-Antichymotrypsin regulates Alzheimer β-amyloid peptide fibril formation. Proc. Natl. Acad. Sci. USA. 92:1995;2313-2317.
29. Erkinjutti T., Wikstrom J., Palo J., Autio L. Dementia among medical patients: Evaluation of 2000 consecutive admissions. Arch. Intern. Med. 146:1986;1921-1926.
30. Ferrier I. N., Pascual J., Charlton B. G., Wright C., Leake A., Griffiths H. W., Fairbairn A. F., Edwardson J. A. Cortisol, ACTH, and dexamethasone concentrations in a psychogeriatric population. Biol. Psychiat. 23:1988;252-260.
31. Fillit H., Ding W. H., Buee L., Kaltman J., Altstiel L., Lawlor B., Wolf-Klein G. Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci. Lett. 129:1991;318-320.
32. Fraser P. E., Nguyen J. T., McLachlan D. R., Abraham C. R., Kirschner D. A. C. α1-Antichymotrypsin binding to Alzheimer Aβ peptides is sequence specific and induces fibril disaggregatiobn in vitro. J. Neurochem. 61:1993;298-305.
33. Gentleman S. M., Graham D. I., Roberts G. W. Molecular pathology of head trauma: Altered beta APP and the aetiology of Alzheimer's disease. Prog. Brain Res. 96:1993;237-246.
34. Ghiso J., Matsubara E., Koudinov A., Choi-Miura N. H., Tomita M., Wisniewski T., Frangione B. The cerebrospinal-fluid soluble form of Alzheimer's amyloid is complexed to SP-40,40 (apolipoprotein J0, an inhibitor of the complement membrane-attack complex. Biochem. J. 293:1993;27-30.
35. Gibson G. E., Blass J. P., Huang F. M., Freeman G. B. The cellular basis of delirium and its relevance to age-related disorders including Alzheimer's disease. Int. Psychogeriat. 3:1991;373-395.
36. Giometto B., Argentiero V., Sanson F., Ongaro G., Tavolato B. Acute-phase proteins in Alzheimer's disease. Eur. Neurol. 28:1988;30-33.
37. Goldgaber D., Harris H. W., Hla T., Maciag T., Donelly R. J., Jacobson J. S., Vitek M. P., Gajdusek D. C. Interleukin-1 regulates synthesis of amyloid β-protein precursor mRNA in human endothelial cells. Proc. Natl. Acad. Sci. USA. 86:1989;7606-7610.
38. Gottfries C. G. Brain, monoamines, and aging. Terry R. D., Bolis C. L., Toffano G. Neural Aging and Its Implications in Neurological Pathology. 1982;161-168 Raven Press, New York.
39. Gottfries C. G. Neurochemical aspects of dementia disorders. Dementia. 1:1990;56-64.
40. Greenwald B. S., Mathe A. A., Mohs R. C., Levy M. I., Johns C. A., Davis K. L. Cortisol and Alzheimer's disease. II. Dexamethasone suppression, dementia severity, and affective symptoms. Am. J. Psychiat. 143:1986;442-446.
41. Griffin W. S. T., Stanley L. C., Ling C., White L., MacLeod V., Perrot L. J., White C. L., Araoz C. Brain interleukin-1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. USA. 86:1989;7611-7615.
42. Griffin W. S. T., Sheng J. G., Roberts G. W., Mrak R. E. Interleukin-1 expression in different plaques types in Alzheimer's disease: Significance in plaque evolution. J. Neuropathol. Exp. Neurol. 54:1995;276-281.
43. Hinds T. R., Kukull W. A., van Belle G., Schellenberg G. D., Villacres E. C., Larson E. B. Relationship between serum alpha 1-antichymotrypsin and Alzheimer's disease. Neurobiol. Aging. 15:1994;21-27.
44. Hofman A., Ott A., Breteler M. M. B., Bots M. L., Slooter A. J. C., van Harskamp F., van Duijn C. M., van Broeckhoven C., Grobbee D. E. Atherosclerosis, apolipoprotein E, and the prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet. 349:1997;151-154.
45. Hoogendijk W. J. G., Pool Ch. W., Troost D., van Zwieten E. J., Swaab D. F. Image analyser-assisted morphometry of the locus coeruleus in Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. Brain. 118:1995;131-143.
46. Huell M., Straus S., Volk B., Berger M., Bauer J. Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients. Acta Neuropathol. 89:1995;544-551.
47. Hyman B. T., Marzloff K., Arriagada P. V. The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution. J. Neuropathol. Exp. Neurol. 52:1993;594-600.
48. Ishii T., Haga S. Immuno-electron microscopic localisation of complements in amyloid fibrils of senile plaques. Acta Neuropathol. 63:1984;296-300.
49. Jiang H., Burdick D., Glabe C. G., Cotman C. W., Tenner A. J. β-Amyloid activates complement by binding to a specific region of the collagen-like domain of C1q A chain. J. Immunol. 152:1994;5050-5059.
50. Itagaki S., McGeer P. L., Akiyama H. Presence of T-cytotoxic suppressor and leucocyte common antigen positive cells in Alzheimer's disease brain tissue. Neurosci. Lett. 91:1988;259-264.
51. Joachim C. L., Morris J. H., Selkoe D. J. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. Am. J. Pathol. 135:1989;309-319.
52. Kalaria R. N. The immunopathology of Alzheimer's disease and some related disorders. Brain Pathol. 3:1993;333-347.
53. Kalman J., Juhasz A., Laird G., Dickens P., Jardanhazy T., Rimanoczy A., Boncz I., Parry-Jones W. L., Janka Z. Serum interleukin-6 levels correlate with the severity of dementia In Down syndrome and in Alzheimer's disease. Acta Neurol. Scand. 96:1996;236-240.
54. Katzman R. Clinical and epidemiological aspects of Alzheimer's disease. Clin. Neurosci. 1:1993;165-170.
55. Klegeris A., Walker D. G., McGeer P. L. Activation of macrophages by Alzheimer β amyloid peptide. Biochem. Biophys. Res. Commun. 199:1994;984-991.
56. Kushner I. The acute phase response: an overview. Methods Enzymol. 163:1988;373-383.
57. Licastro F., Parnetti L., Morini M. C., Davis L. J., Cucinotta D., Gaiti A., Senin U. Acute phase reactant alpha 1-antichymotrypsin is increased in cerebrospinal fluid and serum of patients with probable Alzheimer disease. Alzheimer Dis. Assoc. Disord. 9:1995;112-118.
58. Lemieux N., Malfoy B., Forrest G. L. Human carbonyl reductase (CBR) localized to band 21q22 by high resolution fluorescence in situ hybridisation displays gene dosage effect in trisomy 21 cells. Genomics. 15:1993;169-172.
59. Lindesay J., MacDonald A., Stark I. Delirium in the Elderly. 1990;Oxford Univ. Press, Oxford.
60. Lipowski Z. J. Delirium: Acute Confusional State. 1990;Oxford Univ. Press, Oxford.
61. Lue L. F., Brachova L., Civin W. H., Rogers J. Inflammation, Aβ deposition, neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. J. Neuropathol. Exp. Neurol. 55:1996;1083-1088.
62. Ma J., Yee A., Brewer H. B. Jr., Das S., Potter H. Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature. 372:1994;92-94.
63. Maat-Schieman M. L. C., Rozemuller A. J., van Duinen S. G., Haan J., Eikelenboom P., Roos R. A. C. Microglia in diffuse plaques in hereditary cerebral hemorrhage with amyloidosis (Dutch): An immunohistochemical study. J. Neuropathol. Exp. Neurol. 53:1994;483-491.
64. Maat-Schieman M. L. C., van Duinen S. G., Bornebroek M., Haan J., Roos R. A. C. Hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D). II. A review of histopathological aspects. Brain Pathol. 6:1996;115-120.
65. Maat-Schieman M. L. C., van Duinen S. G., Rozemuller A. J. M., Haan J., Roos R. A. C. Association of vascular amyloid β and cells of the mononuclear phagocytes system in hereditary cerebral hemorrhage with amyloidosis (Dutch) and Alzheimer's disease. J. Neuropathol. Exp. Neurol. 56:1997;273-284.
66. Mann D. M., Esiri M. M. The pattern of acquisition of plaques and tangles in the human brains of patients under 50 years of age with Down's syndrome. J. Neurol. Sci. 89:1989;169-179.
67. Mann D. M. A., Younis N., Jones D., Stoddart R. W. The time course of pathological events in Down's syndrome with particular reference to the involvement of the microglial cells and deposits of β/A4. Neurodegeneration. 1:1992;201-215.
68. Matsubara E., Hirai S., Amari M., Shoji M., Yamaguchi H., Okamoto K., Ishiguro K., Harigaya Y., Wakabayashi K. α1-Antichymotrypsin as a possible biomedical marker for Alzheimer-type dementia. Ann. Neurol. 28:1990;561-567.
69. May P. C., Lampert-Etchells M., Johnson S. A., Poirier J., Martess J. N., Finch C. E. Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat. Neuron. 5:1990;831-839.
70. McClain C. J., Cohen D., Ott L., Dinarello C. A., Young B. Ventricular fluid interleukin-1 activity in patients with head injury. J. Lab. Clin. Med. 110:1987;48-54.
71. McGeer P. L., Akiyama H., Itagaki S., McGeer E. G. Immune system response in Alzheimer's disease. Can. J. Neuro. Sci. 16:1989;516-527.
72. McGeer P. L., Kawanata T., Walker D. G. Distribution of clusterin in Alzheimer brain tissue. Brain Res. 579:1992;337-341.
73. McGeer P. L., McGeer E. G. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Rev. 21:1995;195-218.
74. McGeer P. L., Schulzer M., McGeer E. G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology. 47:1996;425-432.
75. McGeer P. L., McGeer E. G. Inflammatory cytokines in the CNS. CNS Drugs. 7:1997;214-228.
76. Meda L., Cassatella M. A., Szendrei G. I., Otvos L. Jr., Baron P., Villalba M., Ferrari D., Rossi F. Activation of microglial cells by β-amyloid protein and interferon-γ Nature. 374:1995;647-650.
77. Molchan S. E., Hill J. L., Mellow A. M., Lawlor B. A., Martinez R., Sunderland T. The dexamethasone suppression test in Alzheimer's disease and major depression: Relationship to dementia severity, depression, and CSF monoamines. Int. Psychogeriat. 2:1990;99-122.
78. Motte J., Williams R. S. Age-related changes in the density and morphology of plaques and neurofibrillary tangles in Down syndrome brain. Acta Neuropathol. 77:1989;535-546.
79. Murray A. M., Levkoff S. E., Wetle T. T., Becket L., Clearly P. D., Scor J. D., Lipsitz L. A., Rowe J. W., Evans D. E. Acute delirium and functional decline in the hospitalized elderly patient. J. Gerontol. 48:1993;181-186.
80. Nottet H. S., Persidsky Y., Sasseville V. G., Nukuna A. N., Bock P., Zhai Q. H., Sharer L. R., McComb R. D., Swindells S., Soderland C., Gendelman H. E. Mechanisms for the transendothelial migration of HIV-1-infected monocytes into brain. J. Immunol. 156:1996;1284-1295.
81. Ogomori K., Kitamoto T., Tateishi J., Sato Y., Suetsaga M., Abe M. Beta-protein amyloid is widely distributed in the central nervous system of patients with Alzheimer's disease. Am. J. Pathol. 134:1989;234-251.
82. Perry E. K., Gibson P. H., Blessed G., Perry R. H., Tomlinson B. E. Neurotransmitter enzyme abnormalities in senile dementia: Choline acetyltransferase and glumatic acid decarboxylase activities in necropsy brain tissue. J. Neurol. Sci. 32:1977;247-265.
83. Potter H. The involvement of astrocytes and an acute phase response in the amyloid deposition of Alzheimer's disease. Prog. Brain Res. 94:1992;447-458.
84. Pouplard-Barthelaix A. Immunological markers and neuropathological lesions in Alzheimer's disease. Pouplard-Barthelaix A., Emile J., Christen Y. Immunology and Alzheimer's Disease. 1988;7-16 Springer Verlag, Berlin.
85. Raadsheer F. C., van Heerikhuize J. J., Lucassen P. J., Hoogendijk W. J., Tilders F. J., Swaab D. F. Corticotropin-releasing hormone mRNA levels in the paraventricular nucleus of patients with Alzheimer's disease and depression. Am. J. Psychiat. 152:1995;1372-1376.
86. Raskind M. A., Peskind E., Rivard M. F., Veith R., Barnes R. The dexamethasone suppression test and cortisol circadiane rhytm in primary degenerative dementia. Am. J. Psychiat. 139:1982;1468-1471.
87. Roberts G. W., Gentleman S. M., Lynch A., Graham D. I. Beta A4 amyloid protein deposition in brain after head trauma. Lancet. 338:1991;1422-1423.
88. Rockwood K. The occurrence and duration of symptoms in the elderly with delirium. J. Gerontol. 48:1993;M162-M166.
89. Rogers J., Lubert-Narod J., Styren S. D., Civin W. H. Expression of immune system-associated antigens by cells of the human central nervous system: Relationship to the pathology of Alzheimer's disease. Neurobiol. Aging. 9:1988;339-349.
90. Rogers J., Cooper N. R., Webster S., Schultz J., McGeer P. L., Styren S. D., Civin W. H., Brachova L., Bradt B., Lieberburg I. Complement activation by β-amyloid in Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 89:1992;10016-10020.
91. Rogers J., Webster S., Lue L. F., Brachova L., Civin W. H., Emmerling M., Shivers B., Walker D., McGeer P. Inflammation and Alzheimer's disease pathogenesis. Neurobiol. Aging. 17:1996;681-686.
92. Royston M. C., Rothwell N. J., Roberts G. W. Alzheimer's disease: Pathology to potential treatments. Trends Pharmacol. Sci. 13:1992;131-133.
93. Rozemuller J. M., Eikelenboom P., Kamphorst W., Stam F. C. Lack of evidence for blood-brain barrier dysfunction in Alzheimer's disease: An immunohistochemical study. Neurobiol. Aging. 9:1988;381-388.
94. Rozemuller J. M., Eikelenboom P., Pals S. T., Stam F. C. Microglial cells around amyloid plaques in Alzheimer's disease express leucocyte adhesion molecules of the LFA-1 family. Neurosci. Lett. 101:1989;288-292.
95. Rozemuller J. M., Eikelenboom P., Stam F. C., Beyreuther K., Masters C. L. A4 protein in Alzheimer's disease: Primary and secondary cellular events in extracellular amyloid deposition. J. Neuropathol. Exp. Neurol. 48:1989;674-691.
96. Rozemuller J. M., Stam F. C., Eikelenboom P. Acute phase proteins are present in amorphous plaques in the cerebral but not in the cerebellar cortex in patients with Alzheimer's disease. Neurosci. Lett. 119:1990;75-78.
97. Rozemuller J. M., Abbink J., Stam F. C., Hack C. E., Eikelenboom P. Distribution pattern and functional state of α1-antichymotrypsin in plaques and vascular amyloid in Alzheimer's disease. Acta Neuropathol. 82:1991;200-207.
98. Rozemuller J. M., Bots G. T. A. M., Roos R. A. C., Eikelenboom P. Acute phase proteins but not activated microglial cells are present in parenchymal β/A4 deposits in the brains of patients with hereditary cerebral hemorrhage with amyloidosis-Dutch type. Neurosci. Lett. 140:1992;137-140.
99. Rumble B., Retallack R., Hilbich C., Simms G., Multhaup G., Martins R., Hockey A., Montgomery P., Beyreuther K., Masters C. L. Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. N. Engl. J. Med. 320:1989;1446-1452.
100. Salbaum J. M., Masters C. L., Beyreuther K. The amyloid gene of Alzheimer's disease and neuronal dysfunction. Boller F., Katzman R., Rascol A., Signal J. L., Christen Y. Biological Markers of Alzheimer's Disease. 1989;118-122 Springer Verlag, Berlin.
101. Selkoe D. J. Normal and abnormal biology of the β-amyloid precursor protein. Annu. Rev. Neurosci. 17:1994;489-517.
102. Singh V. K., Guthinkonda P. Circulating cytokines in Alzheimer's disease. J. Psychiat. Res. 31:1997;657-660.
103. Snow A. D., Sekiguchi R., Nochlin D., Fraser P., Kimata K., Mizutani A., Arai M., Schreier W. A., Morgan D. G. An important role of heparan sulphate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar β-amyloid in the rat brain. Neuron. 12:1994;219-234.
104. Snow A. D., Sekiguchi R. T., Nochlin D., Kalaria R. N., Kimata K. Heparan sulphate proteoglycan in diffuse plaque of hippocampus but not of cerebellum in Alzheimer's disease brain. Am. J. Pathol. 144:1994;337-347.
105. Spar J. E., Gerner R. Does the dexamethasone suppression test distinguish dementia from depression. Am. J. Psychiat. 139:1982;238-240.
106. Stefano G. B., Bilfinger T. V., Fricchione G. L. The immuno-neuro-link and the macrophage:postcardiotomy delirium, HIV-associated dementia and psychiatry. Prog. Neurobiol. 42:1994;475-488.
107. Tagliavini F., Giaccone G., Frangione B., Bugiani O. Preamyloid deposits in the cerebral cortex of patients with Alzheimer's disease and nondemented elderly. Neurosci. Lett. 93:1988;191-196.
108. Taylor G. M. Altered expression of lymphocyte functional antigen in Down syndrome. Immunol. Today. 8:1987;366-369.
109. Tomlison B. E., Irving D., Blessed G. Cell loss in the locus coeruleus in senile dementia of Alzheimer type. J. Neurol. Sci. 49:1981;419-428.
110. Van Dam A-M., de Vries H. E., Kuiper J., Zijlstra F. J., de Boer A. G., Tilders F. J. H., Berkenbosch F. Interleukin-1 receptors on rat brain endothelial cells: a role in neuroimmune interaction. FASEB J. 10:1996;351-356.
111. Vandenabeele W., Fiers W. Is amyloidogenesis during Alzheimer's disease due to an Il-1/Il-6-mediated 'acute phase response' in the brain. Immunol. Today. 12:1991;217-219.
112. Van Gool J. H., van Vugt, Helle M., Aarden L. A. The relation among stress, adrenalin, interleukin 6 and acute phase proteins in the rat. Clin. Immun. Immunopathol. 57:1990;200-210.
113. Van Duijn C. M., Hofman A. Risk factors for Alzheimer's disease: The EURODEM collaborative re-analysis of case-control studies. Neuroepidemiology. 11:1991;106-113.
114. Van Muiswinkel F. L., Veerhuis R., Eikelenboom P. Amyloid β protein (Aβ) primes cultured rat microglial cells for an enhanced phorbol-myristate-acetate induced respiratory burst activity. J. Neurochem. 66:1996;2468-2476.
115. Veerhuis R., van der Valk P., Janssen I., Zhan S. S., Van Nostrand W. E., Eikelenboom P. Complement activation in amyloid plaques in Alzheimer's disease does not proceed further than C3. Virchows Arch. 426:1995;603-610.
116. Verbeek M. M., Otte-Höller I., Westphal J. R., Wesseling P., Ruiter D. J., de Waal R. M. W. Accumulation of intercellular adhesion molecule-1 in senile plaques in brain tissue of patients with Alzheimer's disease. Am. J. Pathol. 144:1994;104-116.
117. Verbeek M. M., Otte-Höller I., Wesseling P., Ruiter D. J., de Waal R. M. W. Differential expression of intercellular adhesion molecule-1 (ICAM-1) in the Aβ-containing lesions in brains of patients with dementia of the Alzheimer-type. Acta Neuropathol. 91:1996;608-615.
118. Verbeek M. M., Eikelenboom P., de Waal R. M. W. Differences between the pathogenesis of senile plaques and congophilic angiopathy in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 56:1997;751-761.
119. Webster S., O'Barr S., Rogers J. Enhanced aggregation and β structure of the amyloid β peptide after coincubation with C1q. J. Neurosci. Res. 39:1994;448-456.
120. Yamaguchi H., Hirai S., Morimatsa M., Sjohi M., Ihara Y. A variety of cerebral amyloid deposits in the brains of Alzheimer-type dementia demonstrated by β-proteinimmuno-staining. Acta Neuropathol. 76:1988;541-549.
121. Zhan S. S., Veerhuis R., Kamphorst W., Eikelenboom P. Distribution of beta amyloid associated proteins in plaques in Alzheimer's disease and in the non-demented elderly. Neurodegeneration. 4:1995;291-297.